Vaginal Estrogen: The Safest, Most Underused Treatment in Menopause

In November 2025, the FDA announced it would remove the boxed warnings from menopausal hormone therapy products, warnings that medical societies had long argued never fit low-dose vaginal estrogen in the first place. So consider this the updated version of an argument we have been making for years, now with the regulator on side.

The syndrome nobody brings up at dinner

The medical name is genitourinary syndrome of menopause (GSM): the thinning and drying of vaginal and urinary tissues as estrogen falls. It affects over half of postmenopausal women, and unlike hot flashes, which eventually fade for most, GSM is progressive. The tissue changes advance without treatment, which is why "give it time" is the one piece of advice guaranteed to fail.

The symptom list is broader than most women expect: dryness and irritation, pain with sex, loss of elasticity, urinary urgency and frequency, burning, and, most under-recognized, recurrent urinary tract infections. A woman in her seventies on her third UTI this year is having a hormone problem at least as often as a hygiene problem, and treating the hormone problem is what breaks the cycle.

Why it's considered safe when systemic hormones need a longer conversation

Dose and destination. A low-dose vaginal estradiol tablet, cream, or ring delivers a tiny amount of hormone directly to the tissue that needs it. Blood levels stay in or near the postmenopausal range, which is why studies have not shown the clot, stroke, or breast cancer signals associated with the systemic doses discussed in our hormone therapy article. The Menopause Society and ACOG have said for years that the class-wide boxed warning was not supported by the evidence for these local products, and the FDA's 2025 labeling action finally reflects that.

• No age cutoff. Guidelines support starting vaginal estrogen at any age, including well past 70, because the safety profile does not deteriorate the way the systemic risk conversation does.
• No progesterone needed for most women. At standard low doses, the endometrial stimulation that requires progesterone with systemic estrogen is not expected.
• Even many breast cancer survivors can use it, in coordination with their oncologist, when moisturizers are not enough. That conversation is individualized, and we are happy to have it jointly with your oncology team.

The full toolkit, ranked

Why so few women get treated

Studies consistently find that most women with GSM are never treated. The reasons stack: patients are embarrassed to raise it, visits are too short for anyone to ask, the old boxed warning frightened both patients and prescribers, and a generation of doctors trained after 2002 simply prescribed less of everything with "estrogen" on the label. Every one of those obstacles is fixable, and the first fix is a visit long enough for the question to come up naturally. Ours is an hour.

How this works at Framework Health

1. We ask, so you don't have to find the opening. Genitourinary symptoms are a standard part of our menopause review, raised matter-of-factly.
2. Examine and confirm. A brief exam distinguishes GSM from the look-alikes (dermatologic conditions, infections) that need different treatment.
3. Match the product to your life. Cream, tablet, or ring, chosen around your preferences, then insurance realities handled up front.
4. Follow up at the right interval. Improvement builds over six to twelve weeks; we check, adjust, and keep it boring, which is the goal.

Questions we hear about this every week

The bottom line

If dryness, painful sex, urgency, or repeat UTIs have crept into your life, you are not stuck with them, and you were never as far from help as the old label made it feel. Vaginal estrogen is effective, low-risk for most women at any age, and finally labeled accordingly. The only real failure mode of this treatment is never being offered it.